Abstract
Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. The present study investigated its application in clinical practice. This single-center, retrospective database analysis included patients with DLBCL treated at the Slovenian Institute of Oncology Ljubljana between 2004 and 2013. Overall survival (OS) and progression-free survival (PFS) were assessed according to International Prognostic Index (IPI) and revised IPI (R-IPI) categories. Overall, 573 patients with DLBCL were included in the study (median follow-up, 45.3 months; range, 0.1-143.0). Patients were categorized as IPI 'low' (n=170; 30%), 'low-intermediate' (n=134; 23%), 'high-intermediate' (n=129; 23%) and 'high' (n=140; 24%) risk. R-IPI groups were indicated with 'very good' (n=59; 10%), 'good' (n=245; 43%) and 'poor' (n=269; 47%) prognosis. Ten-year OS and PFS rates were 51 and 72%, respectively; median OS was 124 months and median PFS was not reached. Ten-year OS rates were 80 and 87% in low-risk and 'very good' prognosis groups, respectively, and 30 and 37% in high-risk and poor prognosis patients, respectively. T...Continue Reading
References
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
May 2, 2006·The Lancet Oncology·Michael PfreundschuhUNKNOWN MabThera International Trial Group
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Nov 16, 2006·Blood·Laurie H SehnJoseph M Connors
Jun 16, 2010·Blood·Bertrand CoiffierHervé Tilly
May 7, 2011·Haematologica·Olivier FitoussiChristian Gisselbrecht
Oct 19, 2012·Radiology and Oncology·Brigita GregoricBarbara Jezersek Novakovic
Nov 22, 2012·The Lancet Oncology·Norbert SchmitzUNKNOWN German High-Grade Lymphoma Study Group (DSHNHL)
Dec 19, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H HolteM Eriksson
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Dec 17, 2014·Blood·Laurie H Sehn, Randy D Gascoyne
Dec 19, 2014·British Journal of Haematology·Noelia PurroyAndrés Lopez
Jan 7, 2015·Cancer Epidemiology·Yang LiShuangge Ma
Jun 10, 2015·Cancer Causes & Control : CCC·Adam J OlszewskiJorge J Castillo
Jul 21, 2015·Nature Medicine·Wyndham H WilsonLouis M Staudt
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H TillyUNKNOWN ESMO Guidelines Committee
Jul 7, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah M StephensSonali M Smith
Sep 9, 2016·F1000Research·Jung Yong HongWon Seog Kim
Citations
Jun 12, 2020·Therapeutic Advances in Vaccines and Immunotherapy·Leena Halim, John Maher
May 21, 2020·Cells·Felix KorellAnita Schmitt
Sep 26, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hee Sang HwangHeounjeong Go
Mar 11, 2021·Therapeutics and Clinical Risk Management·Barbara Jezeršek NovakovićAleksander Novaković
May 22, 2021·Scientific Data·Damir VrabacPranav Rajpurkar
Aug 7, 2021·Pharmaceuticals·Manar HammoodJeffrey V Leyton